Connie Desarden
Internal Medicine · Wauwatosa, WINPI 1306100227
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.1% of the total across 251 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,244 and has fallen 94.2% since, to $130 in 2025. Among internal medicine clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 251 payments — averaging $24.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$958
- AbbVie$726
- Lilly USA, LLC$614
- Esperion Therapeutics, Inc.$342
- Amgen$331
- plus $2K from 27 others
What the payments were for
- Speaking & faculty fees$160%
- Grants$59610%
- Food & beverage$5,56090%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 23 | $1,112 |
| AstraZeneca | 28 | $958 |
| AbbVie | 30 | $726 |
| Lilly USA, LLC | 36 | $614 |
| Esperion Therapeutics, Inc. | 13 | $342 |
| Amgen | 17 | $331 |
| Novartis | 11 | $226 |
| Boehringer Ingelheim | 10 | $197 |
| GSK | 12 | $188 |
| Johnson & Johnson | 10 | $188 |
| Amneal Pharmaceuticals LLC | 9 | $183 |
| Astellas Pharma US Inc | 8 | $173 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $164 |
| Pfizer | 8 | $144 |
| Boston Scientific | 1 | $124 |
| Bayer | 4 | $87 |
| Idorsia Pharmaceuticals US Inc | 4 | $69 |
| Dexcom, Inc. | 2 | $57 |
| Philips North America LLC | 2 | $37 |
| Merck | 2 | $25 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| Arbor Pharmaceuticals, Inc. | 1 | $20 |
| Ironwood Pharmaceuticals, Inc | 1 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Medicure Pharma Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Exact Sciences | 1 | $15 |
| IBSA Pharma Inc. | 1 | $15 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| Dynavax Technologies Corporation | 1 | $13 |
| Acerus Pharmaceuticals Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,172 in reported general payments places this provider in the 95th percentile of 1,411 internal medicine providers in Wisconsin.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 43 | $53,974 |
| Repatha SureclickEvolocumab | 29 | $15,674 |
| OzempicSemaglutide | 12 | $11,008 |
| SynthroidLevothyroxine Sodium | 15 | $1,390 |
| Duloxetine Hcl | 13 | $1,334 |
| Sertraline Hcl | 12 | $933 |
| Levothyroxine Sodium | 87 | $892 |
| Rosuvastatin Calcium | 62 | $630 |
| Chlorthalidone | 19 | $351 |
| Trazodone Hcl | 21 | $344 |
| Losartan Potassium | 40 | $338 |
| Metoprolol Succinate | 22 | $311 |
| Valsartan | 12 | $298 |
| Atorvastatin Calcium | 31 | $256 |
| Fluoxetine Hcl | 11 | $240 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $614 | $53,97443 claims |
| Novo NordiskOzempic | $1,112 | $11,00812 claims |
| AbbVieSynthroid | $726 | $1,39015 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $183 | $89287 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,411 internal medicine providers in Wisconsin.
Other internal medicine in Wauwatosa
- Haroon ZubairWauwatosa$40K
- Charles WaisbrenWauwatosa$14K
- Jeremiah DeptaMilwaukee$723K
- James KuplicSheboygan$201K
- Erik StilpMilwaukee$116K
- Christopher WeberGermantown$113K
- Alejandro EismaWinnebago$84K
- Hammam ShereefMilwaukee$55K
- Brian SchreiberNeenah$49K
- Kaye-Eileen WillardRacine$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.